ArticlePloS one2011
High-throughput identification of potential minor histocompatibility antigens by MHC tetramer-based screening: feasibility and limitations.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 32 citations in OpenAlex.
- PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors.The Journal of clinical investigation · 2014Trial
- A mass cytometry method pairing T cell receptor and differentiation state analysis.Nature immunology · 2024Article
- Article
- A mass cytometry approach to track the evolution of T cell responses during infection and immunotherapy by paired T cell receptor repertoire and T cell differentiation state analysis.bioRxiv : the preprint server for biology · 2024Article
- Immunopathogenic mechanisms and modulatory approaches to graft-versus-host disease prevention in acute myeloid leukaemia.Best practice & research. Clinical haematology · 2023Review
- T-Cell Immunotherapies Targeting Histocompatibility and Tumor Antigens in Hematological Malignancies.Frontiers in immunology · 2020Review
- Article
- Human CD8+ CD57- TEMRA cells: Too young to be called "old".PloS one · 2017Article
- Minor histocompatibility Ags: identification strategies, clinical results and translational perspectives.Bone marrow transplantation · 2016Review
- The Value of Online Algorithms to Predict T-Cell Ligands Created by Genetic Variants.PloS one · 2016Article
- Strategies for the identification of T cell-recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2015Review
- Broadening the repertoire of melanoma-associated T-cell epitopes.Cancer immunology, immunotherapy : CII · 2015Article
- Identification of minor histocompatibility antigens based on the 1000 Genomes Project.Haematologica · 2014Article
- T-cell responses to oncogenic merkel cell polyomavirus proteins distinguish patients with merkel cell carcinoma from healthy donors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014Article
- A Good Manufacturing Practice procedure to engineer donor virus-specific T cells into potent anti-leukemic effector cells.Haematologica · 2014Article
- High-throughput identification of antigen-specific TCRs by TCR gene capture.Nature medicine · 2013Article
- The human leukocyte antigen-presented ligandome of B lymphocytes.Molecular & cellular proteomics : MCP · 2013Article
- Vaccinomics, adversomics, and the immune response network theory: individualized vaccinology in the 21st century.Seminars in immunology · 2013Review
- Conditional ligands for Asian HLA variants facilitate the definition of CD8+ T-cell responses in acute and chronic viral diseases.European journal of immunology · 2013Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
T-cell recognition of minor histocompatibility antigens (MiHA) plays an important role in the graft-versus-tumor (GVT) effect of allogeneic stem cell transplantation (allo-SCT). However, the number of MiHA identified to date remains limited, making clinical application of MiHA reactive T-cell infusion difficult. This study represents the first attempt of genome-wide prediction of MiHA, coupled to the isolation of T-cell populations that react with these antigens. In this unbiased high-throughput MiHA screen, both the possibilities and pitfalls of this approach were investigated. First, 973 polymorphic peptides expressed by hematopoietic stem cells were predicted and screened for HLA-A2 binding. Subsequently a set of 333 high affinity HLA-A2 ligands was identified and post transplantation samples from allo-SCT patients were screened for T-cell reactivity by a combination of pMHC-tetramer-based enrichment and multi-color flow cytometry. Using this approach, 71 peptide-reactive T-cell populations were generated. The isolation of a T-cell line specifically recognizing target cells expressing the MAP4K1(IMA) antigen demonstrates that identification of MiHA through this approach is in principle feasible. However, with the exception of the known MiHA HMHA1, none of the other T-cell populations that were generated demonstrated recognition of endogenously MiHA expressing target cells, even though recognition of peptide-loaded targets was often apparent. Collectively these results demonstrate the technical feasibility of high-throughput analysis of antigen-specific T-cell responses in small patient samples. However, the high-sensitivity of this approach requires the use of potential epitope sets that are not solely based on MHC binding, to prevent the frequent detection of T-cell responses that lack biological relevance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.